Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totalling 151,700 shares, a decline of 16.0% from the March 31st total of 180,600 shares. Currently, 2.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 213,100 shares, the short-interest ratio is currently 0.7 days.

Exicure Price Performance

Shares of NASDAQ XCUR opened at $0.50 on Friday. Exicure has a 12-month low of $0.36 and a 12-month high of $1.50. The company has a market capitalization of $4.32 million, a PE ratio of 0.30 and a beta of 1.31. The firm’s 50-day moving average is $0.61 and its two-hundred day moving average is $0.60.

Insider Buying and Selling

In other Exicure news, major shareholder Co. Ltd. Dgp sold 3,400,000 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.32, for a total value of $4,488,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.90% of the stock is owned by insiders.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.